Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients.

Date publication

mars 2004

Journal

Annals of oncology : official journal of the European Society for Medical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier

Tous les auteurs :
Ducreux M, Mitry E, Ould-Kaci M, Boige V, Seitz JF, Bugat R, Breau JL, Bouché O, Etienne PL, Tigaud JM, Morvan F, Cvitkovic E, Rougier P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/14998850

Résumé

A randomized phase II, open-label multicenter study evaluating oxaliplatin alone (OXA), infusional 5-fluorouracil alone (5-FU) and an oxaliplatin/infusional 5-FU combination (OXFU) in untreated, advanced pancreatic carcinoma (APC).

Mots clés

Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Female, Fluorouracil, administration & dosage, Humans, Infusions, Intravenous, Liver Neoplasms, drug therapy, Male, Middle Aged, Organoplatinum Compounds, administration & dosage, Pancreatic Neoplasms, drug therapy, Survival Rate

Référence

Ann. Oncol.. 2004 Mar;15(3):467-73